TITLE

Chapter 12: Chronic Myeloproliferative Disorders

AUTHOR(S)
Finnegan, Kathy
PUB. DATE
January 2007
SOURCE
Hematology in Practice;2007, p187
SOURCE TYPE
Book
DOC. TYPE
Book Chapter
ABSTRACT
Chapter 12 of the book "Hematology in Practice" is presented. It focuses on chronic myeloproliferative disorders (CMPD). It describes the clinical features and symptoms of chronic myelogenous leukemia (CML), pathophysiology, and laboratory diagnosis. It discusses the link between erythroid activity and progression of polycythemia vera (PV), as well as prognosis for this condition. Also included are the peripheral blood and bone findings in essential thrombocytopenia, along with the causes of relative thrombocytosis.
ACCESSION #
28628519

 

Related Articles

  • Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-AB L-negative myeloprol iferative neoplasms (MPNs). Reilly, J. T. // Leukemia (08876924);Dec2008 Supplement, Vol. 22, pP111 

    The frequency of cytogenetic abnormalities in the Philadelphia-negative myeloproliferative neoplasms (MPNs) varies from approximately 30% in primary myelofibrosis (PMF) to less than 5% in essential thrombocytosis (ET). The spectrum of aberrations is heterogeneous, ranging from gains and losses...

  • Myeloproliferative disorders: A practical review.  // Patient Care;9/30/1998, Vol. 32 Issue 15, p37 

    Focuses on polycythemia vera (PV), myelofibrosis (MF), thrombocythemia (ET) and chronic myelocytic leukemia (CML) which are termed as myeloproliferative disorders. What are myeloproliferative disorders; Symptoms of these disorders; Diagnosis of these disorders; Treatment procedure for these...

  • Pathology Consultation on Myeloproliferative Neoplasms. Schmidt, Amy E.; Oh, Stephen T. // American Journal of Clinical Pathology;Jul2012, Vol. 138 Issue 1, p12 

    In 2008, the World Health Organization (WHO) revised the classification system for myeloproliferative neoplasms (MPNs). MPNs include chronic myelogenous leukemia, essential thrombocythemia, polycythemia vera, primary myelofibrosis, and several other disorders. The newer classification system...

  • JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Kilpivaara, O.; Levine, R. L. // Leukemia (08876924);Dec2008 Supplement, Vol. 22, pP106 

    Although it has long been known that the myeloproliferative neoplasms (MPN) polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are clonal hematopoietic stem-cell disorders, for many years the genetic basis for these disorders was elusive. A new era in MPN...

  • Chronic myeloproliferative disorders.  // Hematology Journal;2004 Supplement 2, Vol. 5, pS92 

    Presents abstracts of studies on chronic myeloproliferative disorders. Novel 53BP1-PDGFRB fusion as target for imatinib in a patient with BCR-ABL negative chronic myeloid leukemia and a T (5;15) (Q33;Q22); Pegylated interferon alpha (Pegintron) for the treatment of high-risk essential...

  • Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor. Marit, Michael R.; Chohan, Manprit; Matthew, Natasha; Kai Huang; Kuntz, Douglas A.; Rose, David R.; Barber, Dwayne L.; Lenting, Peter J. // PLoS ONE;Aug2012, Vol. 7 Issue 8, Special section p1 

    Background: The non-receptor tyrosine kinase JAK2 is implicated in a group of myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. JAK2-selective inhibitors are currently being evaluated in clinical trials. Data from drug-resistant...

  • Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN). Price, Gregory L.; Davis, Keith L.; Karve, Sudeep; Pohl, Gerhardt; Walgren, Richard A. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Purpose: Non-CML myeloproliferative neoplasms (MPN) include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). Reported median overall survival (OS) ranges from a few to several years for MF, a decade or more for ET and PV. The study objective was to compare US...

  • Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. Geyer, Holly L.; Dueck, Amylou C.; Scherber, Robyn M.; Mesa, Ruben A. // Mediators of Inflammation;10/11/2015, Vol. 2015, p1 

    Myeloproliferative neoplasms (essential thrombocythemia, ET; polycythemia vera, PV; myelofibrosis, MF) are monoclonal malignancies associated with genomic instability, dysregulated signaling pathways, and subsequent overproduction of inflammatory markers. Acknowledged for their debilitating...

  • Determination of prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution. SHINICHI ITO; YUTAKA TSUTSUMI; HIROYUKI OHIGASHI; SOUICHI SHIRATORI; TAKANORI TESHIMA // Molecular & Clinical Oncology;Jan2016, Vol. 4 Issue 1, p51 

    Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocytosis (ET) and primary myelofibrosis (PMF), are clonal hematopoietic diseases. A single-institution retrospective analysis was performed, including 71 MPN patients diagnosed...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics